Marion Jones Returns to Boston Marathon After Rare Disease Recovery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 hours ago
0mins
Should l Buy EHC?
Source: CNBC
- Rare Disease Diagnosis: Marion Jones was ultimately diagnosed with Neuromyelitis Optica (NMO) after multiple medical consultations, a rare autoimmune disorder that affects the optic nerves and spinal cord, leading to partial paralysis and a significant decline in her quality of life.
- Challenging Rehabilitation: At Encompass Rehabilitation Hospital, Jones underwent three hours of intensive therapy daily, and through her dedication, she progressed from being wheelchair-bound to using a walker, showcasing remarkable recovery progress.
- Reviving Running Aspirations: During an outpatient therapy session, Jones was challenged to run on a treadmill, managing only 30 seconds initially, but this reignited her passion for running, allowing her to gradually increase her distance from one minute to a mile, rekindling her athletic dreams.
- Victory at Boston Marathon: Jones is set to complete the Boston Marathon, earning the Abbott World Marathon Majors Six Star Finisher Medal, symbolizing her triumph over adversity, while also raising funds for the rare disease community, reflecting her resilience and commitment to advocacy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EHC
Wall Street analysts forecast EHC stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 106.390
Low
134.00
Averages
146.75
High
160.00
Current: 106.390
Low
134.00
Averages
146.75
High
160.00
About EHC
Encompass Health Corporation is an owner and operator of inpatient rehabilitation hospitals in the United States. The Company provides compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and treatments to maximize recovery. It operates hospitals in 38 states and Puerto Rico, with concentrations in Florida and Texas. It operates approximately 166 inpatient rehabilitation hospitals. Its inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive patient care services. It provides care to patients who suffer from cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures and a variety of debilitating neurological conditions. Its hospitals have settings for treating the debilitating effects of the COVID-19 virus, such as significant muscle weakness, cognitive impairments, shortness of breath with activity and malnutrition.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Marion Jones Returns to Boston Marathon After Rare Disease Recovery
- Rare Disease Diagnosis: Marion Jones was ultimately diagnosed with Neuromyelitis Optica (NMO) after multiple medical consultations, a rare autoimmune disorder that affects the optic nerves and spinal cord, leading to partial paralysis and a significant decline in her quality of life.
- Challenging Rehabilitation: At Encompass Rehabilitation Hospital, Jones underwent three hours of intensive therapy daily, and through her dedication, she progressed from being wheelchair-bound to using a walker, showcasing remarkable recovery progress.
- Reviving Running Aspirations: During an outpatient therapy session, Jones was challenged to run on a treadmill, managing only 30 seconds initially, but this reignited her passion for running, allowing her to gradually increase her distance from one minute to a mile, rekindling her athletic dreams.
- Victory at Boston Marathon: Jones is set to complete the Boston Marathon, earning the Abbott World Marathon Majors Six Star Finisher Medal, symbolizing her triumph over adversity, while also raising funds for the rare disease community, reflecting her resilience and commitment to advocacy.
See More
Pomerantz LLP Investigates Encompass Health Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Encompass Health Corporation, focusing on whether its executives engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Safety Issues Exposed: An article by The New York Times reported that Encompass-operated for-profit hospitals perform below average on key safety measures, with 34 facilities rated by Medicare as having significantly higher rates of preventable readmissions, potentially triggering regulatory scrutiny and legal liabilities.
- Significant Stock Drop: Following the publication of the report, Encompass's stock price fell by $12.39 on July 15, 2025, a decline of 10.35%, closing at $107.28 per share, reflecting market concerns over the company's operational safety.
- Potential Legal Consequences: This investigation may lead to a class action lawsuit, with Pomerantz LLP, a prominent securities litigation firm, potentially seeking damages for affected investors, further impacting the company's reputation and financial standing.
See More
Pomerantz LLP Investigates Encompass Health Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Encompass Health Corporation and its executives for potential securities fraud or other unlawful business practices, which may lead to significant investor losses.
- Safety Issues Exposed: An article published by The New York Times on July 15, 2025, alleged that for-profit hospitals operated by Encompass perform below average on key safety measures, with 34 facilities rated as having significantly higher rates of preventable readmissions, potentially undermining investor confidence.
- Stock Price Plunge: Following the publication of the article, Encompass's stock price fell by $12.39, a decline of 10.35%, closing at $107.28 per share, reflecting market concerns regarding the safety of the company's operations.
- Potential Legal Action: The investigation by Pomerantz LLP may lead to a class action lawsuit, with investors encouraged to contact the firm to explore joining the action, which could further impact Encompass's market performance.
See More
Encompass Health to Report Q1 2026 Results on April 30
- Earnings Announcement Schedule: Encompass Health will report its Q1 2026 results after market close on April 30, 2026, demonstrating the company's commitment to financial transparency, which is expected to positively impact investor confidence.
- Investor Conference Call: The company will host an investor conference call on May 1, 2026, at 10 a.m. ET to discuss its results, providing access via 800-267-6316, ensuring timely information dissemination to investors.
- Global Business Overview: Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the U.S., with 174 hospitals across 39 states and Puerto Rico, showcasing its leadership and market influence in the rehabilitation healthcare sector.
- Industry Recognition: The company is recognized as America's Most Awarded Leader in Inpatient Rehabilitation by Newsweek and Statista, and ranks among Fortune's World's Most Admired Companies™, further solidifying its reputation and appeal in the healthcare industry.
See More
Encompass Health to Report Q1 2026 Results on April 30
- Earnings Release Schedule: Encompass Health will report its Q1 2026 results after market close on April 30, 2026, providing key financial metrics and operational performance insights that will help investors assess the company's future growth potential.
- Investor Conference Call: The company will host an investor conference call at 10 a.m. ET on May 1, 2026, to discuss the earnings results, which is expected to attract significant attention from analysts and investors, thereby enhancing market transparency.
- Global Business Overview: Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the U.S., with 174 hospitals across 39 states and Puerto Rico, demonstrating its leadership position in the healthcare sector by providing high-quality rehabilitative care.
- Industry Recognition: The company has been recognized by Newsweek and Statista as America's Most Awarded Leader in Inpatient Rehabilitation and ranks among Fortune's World's Most Admired Companies and Forbes' America's Best Companies, reflecting its strong reputation and competitive advantage in the industry.
See More
AppLovin Shares Surge 5% on Bullish Wall Street Reports
- AppLovin Revenue Upgrade: BTIG raised AppLovin's first-quarter revenue estimate to $1.82 billion, exceeding consensus, reflecting healthier performance from non-gaming marketers, which is expected to drive further stock price appreciation.
- Encompass Health Surge: Shares of Encompass Health jumped over 6% after the Centers for Medicare & Medicaid Services proposed a 2.4% rate increase for fiscal year 2027, indicating positive policy changes for the healthcare sector.
- Kratos Defense Rallies 8%: Jefferies upgraded Kratos from hold to buy with a 12-month price target of $85, highlighting a $14 billion opportunity pipeline in weapons that could drive over 30% compound annual growth in 2028 earnings estimates.
- Soleno Therapeutics Soars 32%: Neurocrine Biosciences announced an agreement to acquire Soleno for $53 per share, valuing the deal at approximately $2.9 billion, which will enhance Neurocrine's leadership in endocrinology and rare diseases.
See More
Marion Jones Returns to Boston Marathon After Rare Disease Recovery
- Rare Disease Diagnosis: Marion Jones was ultimately diagnosed with Neuromyelitis Optica (NMO) after multiple medical consultations, a rare autoimmune disorder that affects the optic nerves and spinal cord, leading to partial paralysis and a significant decline in her quality of life.
- Challenging Rehabilitation: At Encompass Rehabilitation Hospital, Jones underwent three hours of intensive therapy daily, and through her dedication, she progressed from being wheelchair-bound to using a walker, showcasing remarkable recovery progress.
- Reviving Running Aspirations: During an outpatient therapy session, Jones was challenged to run on a treadmill, managing only 30 seconds initially, but this reignited her passion for running, allowing her to gradually increase her distance from one minute to a mile, rekindling her athletic dreams.
- Victory at Boston Marathon: Jones is set to complete the Boston Marathon, earning the Abbott World Marathon Majors Six Star Finisher Medal, symbolizing her triumph over adversity, while also raising funds for the rare disease community, reflecting her resilience and commitment to advocacy.
See More
Pomerantz LLP Investigates Encompass Health Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Encompass Health Corporation, focusing on whether its executives engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Safety Issues Exposed: An article by The New York Times reported that Encompass-operated for-profit hospitals perform below average on key safety measures, with 34 facilities rated by Medicare as having significantly higher rates of preventable readmissions, potentially triggering regulatory scrutiny and legal liabilities.
- Significant Stock Drop: Following the publication of the report, Encompass's stock price fell by $12.39 on July 15, 2025, a decline of 10.35%, closing at $107.28 per share, reflecting market concerns over the company's operational safety.
- Potential Legal Consequences: This investigation may lead to a class action lawsuit, with Pomerantz LLP, a prominent securities litigation firm, potentially seeking damages for affected investors, further impacting the company's reputation and financial standing.
See More
Pomerantz LLP Investigates Encompass Health Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Encompass Health Corporation and its executives for potential securities fraud or other unlawful business practices, which may lead to significant investor losses.
- Safety Issues Exposed: An article published by The New York Times on July 15, 2025, alleged that for-profit hospitals operated by Encompass perform below average on key safety measures, with 34 facilities rated as having significantly higher rates of preventable readmissions, potentially undermining investor confidence.
- Stock Price Plunge: Following the publication of the article, Encompass's stock price fell by $12.39, a decline of 10.35%, closing at $107.28 per share, reflecting market concerns regarding the safety of the company's operations.
- Potential Legal Action: The investigation by Pomerantz LLP may lead to a class action lawsuit, with investors encouraged to contact the firm to explore joining the action, which could further impact Encompass's market performance.
See More
Encompass Health to Report Q1 2026 Results on April 30
- Earnings Announcement Schedule: Encompass Health will report its Q1 2026 results after market close on April 30, 2026, demonstrating the company's commitment to financial transparency, which is expected to positively impact investor confidence.
- Investor Conference Call: The company will host an investor conference call on May 1, 2026, at 10 a.m. ET to discuss its results, providing access via 800-267-6316, ensuring timely information dissemination to investors.
- Global Business Overview: Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the U.S., with 174 hospitals across 39 states and Puerto Rico, showcasing its leadership and market influence in the rehabilitation healthcare sector.
- Industry Recognition: The company is recognized as America's Most Awarded Leader in Inpatient Rehabilitation by Newsweek and Statista, and ranks among Fortune's World's Most Admired Companies™, further solidifying its reputation and appeal in the healthcare industry.
See More
Encompass Health to Report Q1 2026 Results on April 30
- Earnings Release Schedule: Encompass Health will report its Q1 2026 results after market close on April 30, 2026, providing key financial metrics and operational performance insights that will help investors assess the company's future growth potential.
- Investor Conference Call: The company will host an investor conference call at 10 a.m. ET on May 1, 2026, to discuss the earnings results, which is expected to attract significant attention from analysts and investors, thereby enhancing market transparency.
- Global Business Overview: Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the U.S., with 174 hospitals across 39 states and Puerto Rico, demonstrating its leadership position in the healthcare sector by providing high-quality rehabilitative care.
- Industry Recognition: The company has been recognized by Newsweek and Statista as America's Most Awarded Leader in Inpatient Rehabilitation and ranks among Fortune's World's Most Admired Companies and Forbes' America's Best Companies, reflecting its strong reputation and competitive advantage in the industry.
See More
AppLovin Shares Surge 5% on Bullish Wall Street Reports
- AppLovin Revenue Upgrade: BTIG raised AppLovin's first-quarter revenue estimate to $1.82 billion, exceeding consensus, reflecting healthier performance from non-gaming marketers, which is expected to drive further stock price appreciation.
- Encompass Health Surge: Shares of Encompass Health jumped over 6% after the Centers for Medicare & Medicaid Services proposed a 2.4% rate increase for fiscal year 2027, indicating positive policy changes for the healthcare sector.
- Kratos Defense Rallies 8%: Jefferies upgraded Kratos from hold to buy with a 12-month price target of $85, highlighting a $14 billion opportunity pipeline in weapons that could drive over 30% compound annual growth in 2028 earnings estimates.
- Soleno Therapeutics Soars 32%: Neurocrine Biosciences announced an agreement to acquire Soleno for $53 per share, valuing the deal at approximately $2.9 billion, which will enhance Neurocrine's leadership in endocrinology and rare diseases.
See More
